Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

[Erratum to: Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP].

Unterecker S, Hefner G, Baumann P, Gründer G, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Haen E, Havemann-Reinecke U, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Waschgler R, Zernig G, Zurek G, Hiemke C.

Nervenarzt. 2019 Sep;90(9):958-960. doi: 10.1007/s00115-019-0766-7. German. No abstract available.

PMID:
31309271
2.

Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey.

Karas Kuželički N, Prodan Žitnik I, Gurwitz D, Llerena A, Cascorbi I, Siest S, Simmaco M, Ansari M, Pazzagli M, Di Resta C, Brandslund I, Schwab M, Vermeersch P, Lunshof JE, Dedoussis G, Flordellis CS, Fuhr U, Stingl JC, van Schaik RH, Manolopoulos VG, Marc J; Pharmacogenomics Education Working Group (PGxEWG); European Society of Pharmacogenomics and Personalized Therapy (ESPT).

Pharmacogenomics. 2019 Jun;20(9):643-657. doi: 10.2217/pgs-2019-0009.

3.

Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts.

Just KS, Turner RM, Dolžan V, Cecchin E, Swen JJ, Gurwitz D, Stingl JC.

Clin Pharmacol Ther. 2019 Aug;106(2):313-316. doi: 10.1002/cpt.1471. Epub 2019 Jun 25. No abstract available.

4.

Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by SLC29A4) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study.

Dawed AY, Zhou K, van Leeuwen N, Mahajan A, Robertson N, Koivula R, Elders PJM, Rauh SP, Jones AG, Holl RW, Stingl JC, Franks PW, McCarthy MI, 't Hart LM, Pearson ER; IMI DIRECT Consortium.

Diabetes Care. 2019 Jun;42(6):1027-1033. doi: 10.2337/dc18-2182. Epub 2019 Mar 18.

PMID:
30885951
5.

The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression.

Amare AT, Schubert KO, Tekola-Ayele F, Hsu YH, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Kato M, Liu YL, Praphanphoj V, Stingl JC, Bobo WV, Tsai SJ, Kubo M, Klein TE, Weinshilboum RM, Biernacka JM, Baune BT.

J Neural Transm (Vienna). 2019 Jan;126(1):35-45. doi: 10.1007/s00702-018-01966-x. Epub 2019 Jan 4.

PMID:
30610379
6.

[Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP].

Unterecker S, Hefner G, Baumann P, Gründer G, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Haen E, Havemann-Reinecke U, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Waschgler R, Zernig G, Zurek G, Hiemke C.

Nervenarzt. 2019 May;90(5):463-471. doi: 10.1007/s00115-018-0643-9. Review. German. Erratum in: Nervenarzt. 2019 Jul 15;:.

PMID:
30446893
7.

Comprehensive Measurements of Intrauterine and Postnatal Exposure to Lamotrigine.

Paulzen M, Stingl JC, Augustin M, Saßmannshausen H, Franz C, Gründer G, Schoretsanitis G.

Clin Pharmacokinet. 2019 Apr;58(4):535-543. doi: 10.1007/s40262-018-0713-y.

PMID:
30255309
8.

In Reply.

Stingl JC, Dormann H, LastName FM.

Dtsch Arztebl Int. 2018 Sep 3;115(35-36):594-595. doi: 10.3238/arztebl.2018.0594b. No abstract available.

9.

Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trial.

Weber-Lassalle K, Harter P, Hauke J, Ernst C, Kommoss S, Marmé F, Weber-Lassalle N, Prieske K, Dietrich D, Borde J, Pohl-Rescigno E, Reuss A, Ataseven B, Engel C, Stingl JC, Schmutzler RK, Hahnen E.

Hum Mutat. 2018 Dec;39(12):2040-2046. doi: 10.1002/humu.23653. Epub 2018 Oct 3.

PMID:
30216591
10.

Repeated fMRI in measuring the activation of the amygdala without habituation when viewing faces displaying negative emotions.

Spohrs J, Bosch JE, Dommes L, Beschoner P, Stingl JC, Geiser F, Schneider K, Breitfeld J, Viviani R.

PLoS One. 2018 Jun 4;13(6):e0198244. doi: 10.1371/journal.pone.0198244. eCollection 2018.

11.

Potential Drug-Drug Interactions in a Cohort of Elderly, Polymedicated Primary Care Patients on Antithrombotic Treatment.

Schneider KL, Kastenmüller K, Weckbecker K, Bleckwenn M, Böhme M, Stingl JC.

Drugs Aging. 2018 Jun;35(6):559-568. doi: 10.1007/s40266-018-0550-6.

12.

Adverse Drug Reactions (ADR) and Emergencies.

Schurig AM, Böhme M, Just KS, Scholl C, Dormann H, Plank-Kiegele B, Seufferlein T, Gräff I, Schwab M, Stingl JC.

Dtsch Arztebl Int. 2018 Apr 13;115(15):251-258. doi: 10.3238/arztebl.2018.0251.

13.

Mindful Pharmacogenetics: Drug Dosing for Mental Health.

Stingl JC.

Am J Psychiatry. 2018 May 1;175(5):395-397. doi: 10.1176/appi.ajp.2018.18020134. No abstract available.

PMID:
29712478
14.

Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.

Amare AT, Schubert KO, Tekola-Ayele F, Hsu YH, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Kato M, Liu YL, Praphanphoj V, Stingl JC, Bobo WV, Tsai SJ, Kubo M, Klein TE, Weinshilboum RM, Biernacka JM, Baune BT.

Front Psychiatry. 2018 Mar 6;9:65. doi: 10.3389/fpsyt.2018.00065. eCollection 2018.

15.

TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians<sup/>.

Schoretsanitis G, Paulzen M, Unterecker S, Schwarz M, Conca A, Zernig G, Gründer G, Haen E, Baumann P, Bergemann N, Clement HW, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud-Sirot E, Laux G, Messer T, Mössner R, Müller MJ, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Silva Gracia M, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Waschgler R, Zurek G, Hiemke C.

World J Biol Psychiatry. 2018 Apr;19(3):162-174. doi: 10.1080/15622975.2018.1439595. Epub 2018 Mar 1. Review.

PMID:
29493375
16.

Population nutrikinetics of green tea extract.

Scholl C, Lepper A, Lehr T, Hanke N, Schneider KL, Brockmöller J, Seufferlein T, Stingl JC.

PLoS One. 2018 Feb 21;13(2):e0193074. doi: 10.1371/journal.pone.0193074. eCollection 2018.

17.

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.

Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P.

Pharmacopsychiatry. 2018 Jan;51(1-02):e1. doi: 10.1055/s-0037-1600991. Epub 2018 Feb 1. No abstract available.

PMID:
29390205
18.

A Computerized Version of the Scrambled Sentences Test.

Viviani R, Dommes L, Bosch JE, Stingl JC, Beschoner P.

Front Psychol. 2018 Jan 9;8:2310. doi: 10.3389/fpsyg.2017.02310. eCollection 2017.

19.

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.

Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P.

Pharmacopsychiatry. 2018 Jan;51(1-02):9-62. doi: 10.1055/s-0043-116492. Epub 2017 Sep 14. Review. Erratum in: Pharmacopsychiatry. 2018 Jan;51(1-02):e1.

20.

Falls: the adverse drug reaction of the elderly and the impact of pharmacogenetics.

Just KS, Schneider KL, Schurig M, Stingl JC, Brockmöller J.

Pharmacogenomics. 2017 Aug;18(13):1281-1297. doi: 10.2217/pgs-2017-0018. Epub 2017 Aug 4. Review.

PMID:
28776468
21.

Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx).

Just KS, Steffens M, Swen JJ, Patrinos GP, Guchelaar HJ, Stingl JC.

Eur J Clin Pharmacol. 2017 Oct;73(10):1247-1252. doi: 10.1007/s00228-017-2292-5. Epub 2017 Jul 2.

22.

Pregnancy exposure to citalopram - Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood.

Paulzen M, Goecke TW, Stingl JC, Janssen G, Stickeler E, Gründer G, Schoretsanitis G.

Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt B):213-219. doi: 10.1016/j.pnpbp.2017.06.030. Epub 2017 Jun 27.

PMID:
28663113
23.

Multimodal MEMPRAGE, FLAIR, and [Formula: see text] Segmentation to Resolve Dura and Vessels from Cortical Gray Matter.

Viviani R, Pracht ED, Brenner D, Beschoner P, Stingl JC, Stöcker T.

Front Neurosci. 2017 May 9;11:258. doi: 10.3389/fnins.2017.00258. eCollection 2017.

24.

The iconography of mourning and its neural correlates: a functional neuroimaging study.

Labek K, Berger S, Buchheim A, Bosch J, Spohrs J, Dommes L, Beschoner P, Stingl JC, Viviani R.

Soc Cogn Affect Neurosci. 2017 Aug 1;12(8):1303-1313. doi: 10.1093/scan/nsx058.

25.

Gene expression and proliferation biomarkers for antidepressant treatment resistance.

Breitfeld J, Scholl C, Steffens M, Laje G, Stingl JC.

Transl Psychiatry. 2017 Mar 14;7(3):e1061. doi: 10.1038/tp.2017.16.

26.

Multimorbidity, polypharmacy and pharmacogenomics in old age.

Brockmöller J, Stingl JC.

Pharmacogenomics. 2017 Apr;18(6):515-517. doi: 10.2217/pgs-2017-0026. Epub 2017 Mar 14. No abstract available.

27.

Multimodal FLAIR/MPRAGE segmentation of cerebral cortex and cortical myelin.

Viviani R, Stöcker T, Stingl JC.

Neuroimage. 2017 May 15;152:130-141. doi: 10.1016/j.neuroimage.2017.02.054. Epub 2017 Feb 28.

PMID:
28254513
28.

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.

Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC.

Clin Pharmacol Ther. 2017 Jul;102(1):37-44. doi: 10.1002/cpt.597. Epub 2017 Feb 13. No abstract available.

29.

Predicting CYP2D6 phenotype from resting brain perfusion images by gradient boosting.

Napolitano G, Stingl JC, Schmid M, Viviani R.

Psychiatry Res Neuroimaging. 2017 Jan 30;259:16-24. doi: 10.1016/j.pscychresns.2016.11.005. Epub 2016 Nov 22.

PMID:
27918912
30.

Proliferation rates and gene expression profiles in human lymphoblastoid cell lines from patients with depression characterized in response to antidepressant drug therapy.

Breitfeld J, Scholl C, Steffens M, Brandenburg K, Probst-Schendzielorz K, Efimkina O, Gurwitz D, Ising M, Holsboer F, Lucae S, Stingl JC.

Transl Psychiatry. 2016 Nov 15;6(11):e950. doi: 10.1038/tp.2016.185.

31.

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.

Biernacka JM, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Baune BT, Kato M, Liu YL, Praphanphoj V, Stingl JC, Tsai SJ, Kubo M, Klein TE, Weinshilboum R.

Transl Psychiatry. 2016 Nov 1;6(11):e937. doi: 10.1038/tp.2016.187. No abstract available.

32.

Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) - study protocol for a pragmatic randomized controlled trial.

Stingl JC, Kaumanns KL, Claus K, Lehmann ML, Kastenmüller K, Bleckwenn M, Hartmann G, Steffens M, Wirtz D, Leuchs AK, Benda N, Meier F, Schöffski O, Holdenrieder S, Coch C, Weckbecker K.

BMC Fam Pract. 2016 Apr 26;17:49. doi: 10.1186/s12875-016-0447-6.

33.

[Personalized drug therapy based on genetics. Possibilities and examples from clinical practice].

Stingl JC, Just KS, Kaumanns K, Schurig-Urbaniak M, Scholl C, von Mallek D, Brockmöller J.

Internist (Berl). 2016 Mar;57(3):289-97. doi: 10.1007/s00108-015-0013-7. Review. German.

PMID:
26830424
34.

Gene regulatory biomarker identification for skin toxicities induced by EGFR inhibitor treatment.

Hichert V, Steffens M, Paul T, Scholl C, Parmar S, Rüdiger S, Schumann C, Seufferlein T, Stingl JC.

Int J Clin Pharmacol Ther. 2015 Dec;53(12):1056-8. doi: 10.5414/CPXCES14EA08.

PMID:
26521924
35.

Where Failure Is Not an Option -Personalized Medicine in Astronauts.

Stingl JC, Welker S, Hartmann G, Damann V, Gerzer R.

PLoS One. 2015 Oct 21;10(10):e0140764. doi: 10.1371/journal.pone.0140764. eCollection 2015.

36.

High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors.

Hasheminasab SM, Tzvetkov MV, Schumann C, Rüdiger S, Boeck S, Heinemann V, Kächele V, Steffens M, Scholl C, Hichert V, Seufferlein T, Brockmöller J, Stingl JC.

Pharmacogenomics. 2015;16(14):1605-19. doi: 10.2217/pgs.15.97. Epub 2015 Sep 30.

PMID:
26419366
37.

[Codeine--Restrictions on use for children and teenagers].

Stingl JC, Rotthauwe J.

Dtsch Med Wochenschr. 2015 Jul;140(14):1093-5. doi: 10.1055/s-0041-102948. Epub 2015 Jul 16. German.

PMID:
26182260
38.

Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.

Probst-Schendzielorz K, Viviani R, Stingl JC.

Expert Opin Drug Metab Toxicol. 2015;11(8):1219-32. doi: 10.1517/17425255.2015.1052791. Epub 2015 Jun 1. Review.

PMID:
26028357
39.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.

Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2015 Aug;98(2):127-34. doi: 10.1002/cpt.147. Epub 2015 Jun 29. Review.

40.

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.

Biernacka JM, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Baune BT, Kato M, Liu YL, Praphanphoj V, Stingl JC, Tsai SJ, Kubo M, Klein TE, Weinshilboum R.

Transl Psychiatry. 2015 Apr 21;5:e553. doi: 10.1038/tp.2015.47. Erratum in: Transl Psychiatry. 2016 Nov 1;6(11):e937.

41.

Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients.

Paul T, Schumann C, Rüdiger S, Boeck S, Heinemann V, Kächele V, Steffens M, Scholl C, Hichert V, Seufferlein T, Stingl JC.

Eur J Cancer. 2014 Jul;50(11):1855-63. doi: 10.1016/j.ejca.2014.04.026. Epub 2014 May 23.

PMID:
24857781
42.

Neural activation in humans during a simple motor task differs between BDNF polymorphisms.

Cárdenas-Morales L, Grön G, Sim EJ, Stingl JC, Kammer T.

PLoS One. 2014 May 14;9(5):e96722. doi: 10.1371/journal.pone.0096722. eCollection 2014.

43.

[Personalised pharmacogenetics. Evidence-based guidelines and clinical application of pharmacogenetic diagnostics].

Stingl JC, Brockmöller J.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Nov;56(11):1509-21. doi: 10.1007/s00103-013-1822-2. Review. German.

PMID:
24170080
44.

PharmGKB summary: venlafaxine pathway.

Sangkuhl K, Stingl JC, Turpeinen M, Altman RB, Klein TE.

Pharmacogenet Genomics. 2014 Jan;24(1):62-72. doi: 10.1097/FPC.0000000000000003. Review. No abstract available.

45.

Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.

Stingl JC, Bartels H, Viviani R, Lehmann ML, Brockmöller J.

Pharmacol Ther. 2014 Jan;141(1):92-116. doi: 10.1016/j.pharmthera.2013.09.002. Epub 2013 Sep 27. Review.

PMID:
24076267
46.

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MT, Ambrosone CB, Beckmann MW, Choi JY, Dieudonné AS, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park BW, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, Wingren S, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE; International Tamoxifen Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2014 Feb;95(2):216-27. doi: 10.1038/clpt.2013.186. Epub 2013 Sep 23.

47.

Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration.

Tzvetkov MV, dos Santos Pereira JN, Meineke I, Saadatmand AR, Stingl JC, Brockmöller J.

Biochem Pharmacol. 2013 Sep 1;86(5):666-78. doi: 10.1016/j.bcp.2013.06.019. Epub 2013 Jul 5.

48.

Use of magnetic resonance imaging in pharmacogenomics.

Viviani R, Lehmann ML, Stingl JC.

Br J Clin Pharmacol. 2014 Apr;77(4):684-94. doi: 10.1111/bcp.12197. Review.

49.

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.

Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, Müller DJ, Gaedigk A, Stingl JC; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2013 May;93(5):402-8. doi: 10.1038/clpt.2013.2. Epub 2013 Jan 16. Review.

50.

HLA polymorphisms influence the development of skin rash arising from treatment with EGF receptor inhibitors.

Fuerst D, Parmar S, Schumann C, Rüdiger S, Boeck S, Heinemann V, Kaechele V, Stiebel K, Paul T, Seufferlein T, Mytilineos J, Stingl JC.

Pharmacogenomics. 2012 Oct;13(13):1469-76. doi: 10.2217/pgs.12.122.

PMID:
23057547

Supplemental Content

Loading ...
Support Center